Alexis Anvekar MD ABIHM
Living Method Peptides: GLP-3
Retatrutide
-once weekly injection
The Research
Retatrutide's evidence base is unusually strong for a compound discussed in peptide circles, because it is being developed through full pharmaceutical trials rather than gray-market use. In 2026 it cleared multiple large Phase 3 studies.
TRIUMPH-1 (obesity)
~2,500 adults with obesity or overweight plus a weight-related condition
At the 12 mg dose, average weight loss of about 28.3% (≈70 lbs) over 80 weeks; roughly 45% of participants lost ≥30% of body weight. A 4 mg dose gave about 19.0% over 80 weeks.
TRIUMPH-1 extension
Participants with baseline BMI ≥35
Continued weight loss to an average of about 30.3% (≈85 lbs) at 104 weeks, with no clear plateau.
TRANSCEND-T2D-1 (type 2 diabetes)
Adults with type 2 diabetes inadequately controlled by diet and exercise
Met primary and key secondary endpoints; A1C reductions up to about 2.0%, plus significant weight loss versus placebo.
For context, roughly 28–30% average weight loss approaches the range historically associated with bariatric surgery, and is higher than the figures reported for current single- and dual-agonist drugs. These are company-reported topline results from well-designed trials — a far stronger basis than the anecdotal or small-study evidence behind many research peptides.
How does it compare to other GLPs in it's class?
Semaglutide (Wegovy) GLP-1
~15% reported weight loss in clinical trials
Tirzepatide (Zepbound) GLP-1 + GIP
~20–22% reported weight loss in clinical trials
Retatrutide GLP-1 + GIP + glucagon
Investigational — not approved
~28–30% reported weight loss in ongoing clinical trials
The pattern across the class is that adding receptor targets has tended to increase average weight loss. Retatrutide's numbers are the highest reported so far.
What is Retatrutide?
Retatrutide is the most potent weight-loss compound yet to emerge from the GLP-1 era — a once-weekly injectable that acts on three hormone systems at once. In large clinical trials it has produced weight loss approaching what is normally seen only with bariatric surgery.
Retatrutide is an investigational, first-in-class peptide that activates three different hormone receptors involved in metabolism: GLP-1, GIP, and glucagon. Because it hits all three, it is often called a “triple agonist” or “triple G.” It is being developed by Eli Lilly and is given as a once-weekly subcutaneous injection.
The widely cited projections from trackers put the NDA filing by Eli Lilly in late 2026, with potential approval in 2027 (possibly slipping to 2028), assuming the remaining trials finish on schedule and the review goes smoothly.
It sits in the same broad family as today's well-known weight and diabetes drugs, but goes a step further in mechanism. Semaglutide (Wegovy / Ozempic) targets one receptor (GLP-1). Tirzepatide (Zepbound / Mounjaro) targets two (GLP-1 and GIP). Retatrutide targets three, adding glucagon-receptor activity, which is thought to further increase energy expenditure on top of appetite reduction.
How it works
-
GLP-1 receptor: slows stomach emptying, increases the feeling of fullness, and reduces appetite — the core mechanism shared across this drug class.
-
GIP receptor: another gut-hormone pathway that complements GLP-1 in regulating blood sugar and appetite; the basis of tirzepatide's added effect.
-
Glucagon receptor: the distinctive third target. Activating it is thought to raise energy expenditure and influence fat metabolism in the liver, potentially adding to weight loss beyond appetite suppression alone.
-
Retatrutide's body-composition data (mostly Phase 2 DXA results) shows roughly 62–69% of weight lost came from fat.
